SCHEMBL16442879

SCHEMBL16442879

Cc1cc(Oc2ccccc2)c(C)cc1OCc1c(C)cccc1-n1nnn(C)c1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 1/20 0.36
PPARG P37231 2/20 0.35
NTRK1 P04629 2/20 0.34
NTRK2 Q16620 2/20 0.34
IGF1R P08069 1/20 0.34
FGFR1 P11362 1/20 0.34
FFAR1 O14842 2/20 0.34
FFAR4 Q5NUL3 1/20 0.34
TRIM24 O15164 1/20 0.34
BRD1 O95696 1/20 0.34
BRPF1 P55201 1/20 0.34
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPT P10636 2/20 0.33
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
MAPK1 P28482 1/20 0.33
KMT2A Q03164 1/20 0.33
NTRK3 Q16288 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18021052 0.90 SLC22A12 (0.39) SLC22A12PPARGNTRK1NTRK2IGF1R
SCHEMBL16442868 0.90 FFAR1 (0.41) PPARGNTRK1NTRK2IGF1RFGFR1
SCHEMBL16442756 0.89 SLC22A12 (0.38) SLC22A12CYP3A4CYP2C9ALDH1A1MAPT
SCHEMBL16683840 0.87 LMNA (0.41) SLC22A12PPARGTRIM24ALDH1A1LMNA
SCHEMBL16442821 0.87 NPC1 (0.40) PPARGALDH1A1MAPTMEN1LMNA
SCHEMBL16442853 0.87 P2RX7 (0.34) SLC22A12PPARGCYP3A4CYP2C9BRD4
SCHEMBL18546258 0.87 NPC1 (0.40) ALDH1A1MAPTMEN1LMNAMAPK1
SCHEMBL16442785 0.87 SLC22A12 (0.35) SLC22A12CYP3A4CYP2C9ALDH1A1MAPT
SCHEMBL16442829 0.86 PPARG (0.39) SLC22A12PPARGFFAR1FFAR4ALDH1A1
SCHEMBL17806095 0.85 SLC22A12 (0.34) SLC22A12CYP3A4CYP2C9ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3029030-B1 TETRAZOLINONE COMPOUND, AND USE THEREFOR SUMITOMO CHEMICAL CO (JP) 2019-09-04 EP disclosed
US-9512090-B2 Tetrazolinone compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-12-06 US disclosed
US-9512090-B2 Tetrazolinone compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-12-06 US disclosed
US-20160159755-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-06-09 US disclosed
US-20160159755-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-06-09 US disclosed
EP-3029030-A1 TETRAZOLINONE COMPOUND, AND USE THEREFOR Sumitomo Chemical Company, Limited (JP) 2016-06-08 EP disclosed
WO-2015016373-A1 TETRAZOLINONE COMPOUND, AND USE THEREFOR 住友化学株式会社 (JP) 2015-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160159755-A1 TETRAZOLINONE COMPOUND AND USE THEREOF CYP1A1, CASP1, TCOF1 SLC22A12 3833/4885PPARG 1135/4885NTRK1 2271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.